Shots:

• The company reported the commercial availability of Livtencity (maribavir) for adults and pediatric patients aged ≥12yrs. with post-transplant CMV infection with/out genotypic resistance with ganciclovir, valganciclovir, cidofovir, or foscarnet
• The company has provided a patient support program that helps the patients to gain access treated with Livtencity along with an educational resources support program and financial assistance options
• Livtencity is an orally bioavailable anti-CMV compound & the only antiviral agent that targets and inhibits the pUL97 protein kinase and its natural substrates that resulted in inhibition of viral DNA replication, encapsidation, and nuclear egress

/ article | Ref: Businesswire | Image: Takeda